Concise review: Umbilical cord blood transplantation: Past, present, and future

Stem Cells Translational Medicine

Volumn 3, Issue 12, 2014, Pages 1435-1443

  Munoz, Javier ^a   Shah, Nina ^b   Rezvani, Katayoun ^b   Hosing, Chitra ^b   Bollard, Catherine M ^c,d   Oran, Betul ^b   Olson, Amanda ^b   Popat, Uday ^b   Molldrem, Jeffrey ^b   McNiece, Ian K ^b   Shpall, Elizabeth J ^b  

^a Banner MD Anderson Cancer Center   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c CHILDREN S NATIONAL HOSPITAL   (United States)

^d GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

Author keywords

Graft versus host disease; Hematopoietic stem cell transplantation; Leukemia; Lymphoma; Transplant related mortality; Umbilical cord blood transplantation

Indexed keywords

CD34 ANTIGEN; CYCLOPHOSPHAMIDE; CYTOKINE; ERYTHROPOIETIN; FLT3 LIGAND; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; HISTONE DEACETYLASE; HLA ANTIGEN; MEGAKARYOCYTE GROWTH AND DEVELOPMENT FACTOR; MELPHALAN; STEM CELL FACTOR; THROMBOPOIETIN; THYMOCYTE ANTIBODY; TUMOR NECROSIS FACTOR;

ACUTE LEUKEMIA; ADENOVIRUS; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; BLOOD DONOR; CHRONIC GRANULOMATOUS DISEASE; CORD BLOOD STEM CELL TRANSPLANTATION; CYTOMEGALOVIRUS; CYTOTOXIC T LYMPHOCYTE; ENGRAFTMENT; GLOBOID CELL LEUKODYSTROPHY; GRAFT FAILURE; GRAFT RECIPIENT; GRAFT VERSUS HOST REACTION; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL; HEMOGLOBINOPATHY; HUMAN; HURLER SYNDROME; IMMUNE DEFICIENCY; MULTICENTER STUDY (TOPIC); NONHUMAN; NUCLEOTIDE SEQUENCE; OUTCOME ASSESSMENT; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REDUCED INTENSITY CONDITIONING; UMBILICAL CORD BLOOD; WHOLE BODY RADIATION; ADULT; ALLOGRAFT; DISEASE FREE SURVIVAL; HEMATOLOGIC NEOPLASMS; HISTORY; IMMUNOSUPPRESSIVE TREATMENT; MORTALITY; PROCEDURES; SURVIVAL RATE; TRENDS;

ADULT; ALLOGRAFTS; CORD BLOOD STEM CELL TRANSPLANTATION; DISEASE-FREE SURVIVAL; HEMATOLOGIC NEOPLASMS; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; SURVIVAL RATE; TRANSPLANTATION CONDITIONING;

EID: 84913570653     PISSN: 21576564     EISSN: 21576580     Source Type: Journal    
DOI: 10.5966/sctm.2014-0151     Document Type: Article

References (114)

1. Ballen KK, King RJ, Chitphakdithai P et al. The national marrow donor program 20 years of unrelated donor hematopoietic cell transplantation. Biol Blood Marrow Transplant 2008;14(suppl):2–7.
2. Barker JN, Byam CE, Kernan NA et al. Availability of cord blood extends allogeneic hema-topoietic stem cell transplant access to racial andethnicminorities.Biol Blood Marrow Trans-plant 2010;16:1541–1548.
3. Broxmeyer HE, Douglas GW, Hangoc G et al. Human umbilical cord blood as a potential source of transplantable hematopoietic stem/progenitor cells. Proc Natl Acad Sci USA 1989;86:3828–3832.
4. Gluckman E, Broxmeyer HA, Auerbach AD et al. Hematopoietic reconstitution in a patient with Fanconi’s anemia by means of umbilical-cord blood from an HLA-identical sibling. N Engl J Med 1989;321:1174–1178.
5. Wagner JE, Rosenthal J, Sweetman R et al. Successful transplantation of HLA-matched and HLA-mismatched umbilical cord blood from unrelated donors: Analysis of engraftment and acute graft-versus-host disease. Blood 1996; 88:795–802.
6. Kurtzberg J, Laughlin M, Graham ML et al. Placental blood as a source of hemato-poietic stem cells for transplantation into unrelated recipients. N Engl J Med 1996;335: 157–166.
7. Barker JN, Krepski TP, DeFor TE et al. Searching for unrelated donor hematopoietic stem cells: Availability and speed of umbilical cord blood versus bone marrow. Biol Blood Marrow Transplant 2002;8:257–260.
8. Hakenberg P, Kögler G, Wernet P. NET-CORD: A cord blood allocation network. Bone Marrow Transplant 1998;22(suppl 1):S17–S18.
9. Petersdorf EW, Gooley TA, Anasetti C et al. Optimizing outcome after unrelated marrow transplantation by comprehensive matching of HLA class I and II alleles in the donor and recipient. Blood 1998;92:3515–3520.
10. Garderet L, Dulphy N, Douay C et al. The umbilical cord blood alphabeta T-cell repertoire: Characteristics of a polyclonal and naive but completely formed repertoire. Blood 1998; 91:340–346.
11. Locatelli F, Rocha V, Chastang C et al. Factors associated with outcome after cord blood transplantation in children with acute leukemia. Blood 1999;93:3662–3671.
12. Michel G, Rocha V, Chevret S et al. Unrelated cord blood transplantation for childhood acute myeloid leukemia: A Eurocord Group analysis. Blood 2003;102:4290–4297.
13. Kurtzberg J, Prasad VK, Carter SL et al. Results of the Cord Blood Transplantation Study (COBLT): Clinical outcomes of unrelated donor umbilical cord blood transplantation in pediatric patients with hematologic malignancies. Blood 2008;112:4318–4327.
14. Eapen M, Rubinstein P, Zhang MJ et al. Outcomes of transplantation of unrelated donor umbilical cord blood and bone marrow in children with acute leukaemia: A comparison study. Lancet 2007;369:1947–1954.
15. Fernandes JF, Rocha V, Labopin M et al. Transplantation in patients with SCID: Mismatched related stem cells or unrelated cord blood? Blood 2012;119:2949–2955.
16. Kamani NR, Walters MC, Carter S et al. Unrelated donor cord blood transplantation for children with severe sickle cell disease: Results of one cohort from the phase II study from the Blood and Marrow Transplant Clinical Trials Network (BMT CTN). Biol Blood Marrow Transplant 2012;18:1265–1272.
17. Escolar ML, Poe MD, Provenzale JM et al. Transplantation of umbilical-cord blood in babies with infantile Krabbe’s disease. N Engl J Med 2005;352:2069–2081.
18. Bhattacharya A, Slatter M, Curtis A et al. Successful umbilical cord blood stem cell transplantation for chronic granulomatous disease. Bone Marrow Transplant 2003;31:403–405.
19. Staba SL, Escolar ML, Poe M et al. Cord-blood transplants from unrelated donors in patients with Hurler’s syndrome. N Engl J Med 2004;350:1960–1969.
20. Boelens JJ, Aldenhoven M, Purtill D et al. Outcomes of transplantation using various he-matopoietic cell sources in children with Hurler syndrome after myeloablative conditioning. Blood 2013;121:3981–3987.
21. Rubinstein P, Carrier C, Scaradavou A et al. Outcomes among 562 recipients of placental-blood transplants from unrelated donors. N Engl J Med 1998;339:1565–1577.
22. Laughlin MJ, Barker J, Bambach B et al. He-matopoietic engraftment and survival in adult recipients of umbilical-cord blood from unre-lateddonors. N Engl J Med 2001;344:1815–1822.
23. Rocha V, Labopin M, Sanz G et al. Transplants of umbilical-cord blood or bone marrow from unrelated donors in adults with acute leukemia. N Engl J Med 2004;351:2276–2285.
24. Laughlin MJ, Eapen M, Rubinstein P et al. Outcomes after transplantation of cord blood or bone marrow from unrelated donors in adults with leukemia. N Engl J Med 2004;351: 2265–2275.
25. Eapen M, Rocha V, Sanz G et al. Effect of graft source on unrelated donor haemopoietic stem-cell transplantation in adults with acute leukaemia: A retrospective analysis. Lancet Oncol 2010;11:653–660.
26. Barker JN, Weisdorf DJ, DeFor TE et al. Transplantation of2partially HLA-matched umbilical cord blood unitstoenhance engraftment in adults with hematologic malignancy. Blood 2005;105:1343–1347.
27. Ramirez P, Wagner JE, De For TE et al. Fac-tors predicting single-unit predominance after double umbilical cord blood transplantation. Bone Marrow Transplant 2012;47:799–803.
28. Gutman JA, Turtle CJ, Manley TJ et al. Single-unit dominance after double-unit umbilical cord blood transplantation coincides with a specific CD8+ T-cell response against the non-engrafted unit. Blood 2010;115:757–765.
29. MacMillan ML, Weisdorf DJ, Brunstein CG et al. Acute graft-versus-host disease after unrelated donor umbilical cord blood transplantation: Analysis of risk factors. Blood 2009;113: 2410–2415.
30. Rodrigues CA, Sanz G, Brunstein CG et al. Analysis of risk factors for outcomes after unrelated cord blood transplantation in adults with lymphoid malignancies: A study by the Eurocord-Netcord and lymphoma working party of the European group for blood and marrow transplantation. J Clin Oncol 2009;27:256–263.
31. Kindwall-Keller TL, Hegerfeldt Y, Meyerson HJ et al. Prospective study of one- vs two-unit umbilical cord blood transplantation following reduced intensity conditioning in adults with hematological malignancies. Bone Marrow Transplant 2012;47:924–933.
32. Brunstein CG, Gutman JA, Weisdorf DJ et al. Allogeneic hematopoietic cell transplantation for hematologic malignancy: Relative risks and benefits of double umbilical cord blood. Blood 2010;116:4693–4699.
33. Barker JN, Weisdorf DJ, DeFor TE et al. Rapid and complete donor chimerism in adult recipients of unrelated donor umbilical cord blood transplantation after reduced-intensity conditioning. Blood 2003;102:1915–1919.
34. Ballen KK, Spitzer TR, Yeap BY et al. Double unrelated reduced-intensity umbilical cord blood transplantationin adults. Biol Blood Marrow Transplant 2007;13:82–89.
35. Brunstein CG, Eapen M, Ahn KW et al. Reduced-intensity conditioning transplantation in acute leukemia: The effect of source of unrelated donor stem cells on outcomes. Blood 2012;119:5591–5598.
36. Brunstein CG, Fuchs EJ, Carter SL et al. Alternative donor transplantation after reduced intensity conditioning: Results of parallel phase 2 trials using partially HLA-mismatched related bone marrow or unrelated double umbilical cord blood grafts. Blood 2011;118:282–288.
37. Wagner JE, Eapen M, Carter SL et al. No survival advantage after double umbilical cord blood (UCB) compared to single UCB transplant in children with hematological malignancy: Results of the blood and marrow transplant clinical trials network (BMT CTN 0501) randomized trial. Available at https://ash.confex.com/ash/2012/webprogram/Paper48413.html. Accessed September 2, 2014.
38. Collins CL, Ahn KW, Wang Z et al. Long-term survival after alternative donor transplantation in children with acute leukemia. J Clin Oncol 2013;31(suppl):10006a.
39. Dahi PB, Ponce DM, Byam C et al. Prospective evaluation of alternative donor availability in 708 patients: Improved allograft access with enlarging CB inventory for all patients including racial and ethnic minorities. Available at https://ash.confex.com/ash/2013/webprogram/Paper60210.html. Accessed September 2, 2014.
40. Bachanova V, Brunstein C, Burns LJ et al. Alternative donor transplantation for adults with lymphoma: Comparison of umbilical cord blood versus 8/8 HLA-matched donor (URD) versus 7/8 URD. Available at https://ash.confex.com/ash/2013/webprogram/Paper57320.html. Accessed September 2, 2014.
41. Stiff PJ, Montesinos P, Peled T et al. Stem Ex (copper chelation based) ex vivo expanded umbilical cord blood stem cell transplantation (UCBT) accelerates engraftment and improves 100 day survival in myeloablated patients compared to a registry cohort undergoing double unit UCBT: Results of a multicenter study of 101 patients with hematologic malignancies. Available at https://ash.confex.com/ash/2013/webprogram/Paper61421.html. Accessed September 2, 2014.
42. Vasileiou S, Baltadakis I, Panitsas F et al. Comparative analysis of cell dose and viability of cord blood units at cryopreservation and at thaw/infusion for unrelated stem cell transplantation in adult recipients. Available at https://bmt.confex.com/tandem/2014/webprogram/Paper4069.html. Accessed September 2, 2014.
43. Ponce DM, Hilden P, Mumaw C et al. High day 28 ST2 biomarker levels predict severe day 100acute graft-versus-hostdiseaseandday180 transplant-related mortality after double-unit cord blood transplantation. Available at https://ash.confex.com/ash/2013/webprogram/Paper60713.html. Accessed September 2, 2014.
44. Poon ML, Linn YC, Lim Z et al. Double unit umbilical cord blood transplant for adults with acute leukemia and myelodysplastic syndrome results in comparable outcome as matched sibling or unrelated donor transplant only after myeloablative conditioning but not reduced intensity conditio. Biol Blood Marrow Transplant 2014;20(suppl):S247.
45. Ghantoji SS, Goddu S, Sreenivasula S et al. Characteristics and outcome of cytomegalo-virus (CMV) infections in 95 cord blood transplant (CBT) recipients: The MD Anderson experience. Biol Blood Marrow Transplant 2014;20(suppl): S223–S224.
46. Barker JN, Ponce DM, Dahi P et al. Double-unit cord blood (CB) transplantation combined with haplo-identical CD34+ cells results in100% CB engraftment with enhanced myeloid CD34+ recovery. Biol Blood Marrow Transplant 2014; 20(suppl):S138–S139.
47. Volodin L, Beitinjaneh A, Salman H et al. Outcomes of double unit umbilical cord blood transplantation using fludarabine/busulfan based reduced intensity conditioning regimen. Biol Blood Marrow Transplant 2014;20(suppl):S142.
48. Ponce DM, Devlin S, Lubin M et al. High disease-free survival and enhanced protection against relapse after double-unit cord blood transplantation(DCB-T) whencomparedtounre-lated donor transplantation (URD-T) in patients with acute leukemia, MDS and CML. Biol Blood Marrow Transplant 2014;20(suppl):S58–S59.
49. National Marrow Donor Program. Adult Allogeneic HCT, by Transplant Type, Cell Source. Available at https://bethematchclinical.org/resources-and-education/hct-presentation-slides/adult-allogeneic-hct,-by-transplant-type,-cell-source/. Accessed August 30, 2014.
50. Appelbaum FR. Hematopoietic-cell transplantation at 50. N Engl J Med 2007;357: 1472–1475.
51. Oran B, Shpall E. Umbilical cord blood transplantation: A maturing technology. Hema-tology (Am Soc Hematol Educ Program) 2012; 2012:215–222.
52. de Lima M, McMannis J, Gee A et al. Transplantation of ex vivo expanded cord blood cells using the copper chelator tetraethylene-pentamine: A phase I/II clinical trial. Bone Marrow Transplant 2008;41:771–778.
53. Delaney C, Heimfeld S, Brashem-Stein C et al. Notch-mediated expansionofhuman cord blood progenitor cells capable of rapid myeloid reconstitution. Nat Med 2010;16:232–236.
54. Robinson SN, Ng J, Niu T et al. Superior ex vivo cord blood expansion following co-culture with bone marrow-derived mesenchymal stem cells. Bone Marrow Transplant 2006;37: 359–366.
55. Kelly SS, Sola CB, de Lima M et al. Ex vivo expansion of cord blood. Bone Marrow Transplant 2009;44:673–681.
56. de Lima M, McNiece I, Robinson SN et al. Cord-blood engraftment with ex vivo mesenchymal-cell coculture. N Engl J Med 2012;367:2305–2315.
57. Frassoni F, Gualandi F, Podestá M et al. Direct intrabone transplant of unrelated cord-blood cells in acute leukaemia: A phase I/II study. Lancet Oncol 2008;9:831–839.
58. Bautista G, Cabrera JR, Regidor C et al. Cord blood transplants supported by co-infusion of mobilized hematopoietic stem cells from a third-party donor. Bone Marrow Transplant 2009;43:365–373.
59. Fernández MN, Regidor C, Cabrera R et al. Unrelated umbilical cord blood transplants in adults: Early recovery of neutrophils by supportive co-transplantation of a low number of highly purified peripheral blood CD34+ cells from an HLA-haploidentical donor. Exp Hematol 2003;31:535–544.
60. Xia L, McDaniel JM, Yago T et al. Surface fucosylation of human cord blood cells augments binding to P-selectin and E-selectin and enhances engraftment in bone marrow. Blood 2004;104:3091–3096.
61. Robinson SN, Simmons PJ, Thomas MW et al. Exvivo fucosylation improves human cord blood engraftment in NOD-SCID IL-2Rg(null) mice. Exp Hematol 2012;40:445–456.
62. Hoggatt J, Singh P, Sampath J et al. Pros-taglandin E2 enhances hematopoietic stem cell homing, survival, and proliferation. Blood 2009; 113:5444–5455.
63. Cutler C, Multani P, Robbins D et al. Prostaglandin-modulated umbilical cord blood hematopoietic stem cell transplantation. Blood 2013;122:3074–3081.
64. Brunstein CG, Miller JS, Cao Q et al. Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: Safety profile and detection kinetics. Blood 2011;117:1061–1070.
65. Shah N, Martin-Antonio B, Yang H et al. Antigen presenting cell-mediated expansion of human umbilical cord blood yields log-scale expansion of natural killer cells with anti-myeloma activity. PLoS One 2013;8: e76781.
66. Hanley PJ, Cruz CR, Savoldo B et al. Functionally active virus-specific T cells that target CMV, adenovirus, and EBV can be expanded from naive T-cell populations in cord blood and will target a range of viral epitopes. Blood 2009;114:1958–1967.
67. Jain N, Liu H, Artz AS et al. Immune recon-stitution after combined haploidentical and umbilical cord blood transplant. Leuk Lym-phoma 2013;54:1242–1249.
68. American Society of Hematology. 50 years in hematology: Research that revolutionized patient care. Available at http://www.hematology.org/About-ASH/50-Years.aspx. Accessed August 30, 2014.
69. Gluckman E, Ruggeri A, Volt F et al. Milestones in umbilical cord blood transplantation. Br J Haematol 2011;154:441–447.
70. Cooper B. The origins of bone marrow as the seedbedof our blood: From antiquity to the time of Osler. Proc (Bayl Univ Med Cent) 2011; 24:115–118.
71. Osgood EE, Riddle MC, Mathews TJ. Aplastic anemia treated with daily transfusions and intravenous marrow: Case report. Ann Intern Med 1939;13:357–367.
72. Congdon CC. Experimental treatment of total-body irradiation injury: A brief review. Blood 1957;12:746–754.
73. Thomas ED, Lochte HL Jr., Cannon JH et al. Supralethal whole body irradiation and isologous marrow transplantationin man. J Clin Invest 1959;38:1709–1716.
74. Thomas ED, Lochte HL Jr., Lu WC et al. Intravenous infusion of bone marrow in patients receiving radiation and chemotherapy. N Engl J Med 1957;257:491–496.
75. Thomas ED, Lochte HL Jr., Ferrebee JW. Irradiationofthe entire bodyandmarrowtrans-plantation: Some observations and comments. Blood 1959;14:1–23.
76. Thomas E, Storb R, Clift RA et al. Bone-marrow transplantation (first of two parts). N Engl J Med 1975;292:832–843.
77. Gatti RA, Meuwissen HJ, Allen HD et al. Immunological reconstitution of sex-linked lymphopenic immunological deficiency. Lancet 1968;2:1366–1369.
78. Graw RG Jr., Lohrmann HP, Bull MI et al. Bone-marrow transplantation following combination chemotherapy immunosuppression (B.A.C.T.) in patients with acute leukemia. Transplant Proc 1974;6:349–354.
79. Bleyer WA, Blaese RM, Bujak JS et al. Long-term remission from acute myelogenous leukemia after bone marrow transplantation andrecovery from acutegraft-versus-host reaction and prolonged immunoincompetence. Blood 1975;45:171–181.
80. Appelbaum FR, Herzig GP, Ziegler JL et al. Successful engraftment of cryopreserved autol-ogous bone marrow in patients with malignant lymphoma. Blood 1978;52:85–95.
81. Thomas ED. The Nobel Lectures in Immunology: The Nobel Prize for Physiology or Medicine, 1990. Bone marrow transplantation: Past, present and future. Scand J Immunol 1994;39:339–345.
82. Laporte JP, Gorin NC, Rubinstein P et al. Cord-blood transplantation from an unrelated donor in an adult with chronic myelog-enous leukemia. N Engl J Med 1996;335: 167–170.
83. Gluckman E, Rocha V, Boyer-Chammard A et al. Outcome of cord-blood transplantation from related and unrelated donors. N Engl J Med 1997;337:373–381.
84. Rocha V, Wagner JE Jr., Sobocinski KA et al. Graft-versus-host disease in children who have received a cord-blood or bone marrow transplant from an HLA-identical sibling. N Engl J Med 2000;342:1846–1854.
85. Cairo MS, Wagner JE. Placental and/or umbilical cord blood: An alternative source of hematopoietic stem cells for transplantation. Blood 1997;90:4665–4678.
86. Sanz GF, Saavedra S, Planelles D et al. Standardized, unrelated donor cord blood transplantation in adults with hematologic malignancies. Blood 2001;98:2332–2338.
87. Shpall EJ, Quinones R, Giller R et al. Trans-plantation of ex vivo expanded cord blood. Biol Blood Marrow Transplant 2002;8:368–376.
88. Kögler G, Sensken S, Airey JA et al. A new human somatic stem cell from placental cord blood with intrinsic pluripotent differentiation potential. J Exp Med 2004;200:123–135.
89. Brunstein CG, Barker JN, Weisdorf DJ et al. Umbilical cord blood transplantation after nonmyeloablative conditioning: Impact on transplantationoutcomesin110 adultswith he-matologic disease. Blood 2007;110:3064–3070.
90. Rocha V, Crotta A, Ruggeri A et al. Double cord blood transplantation: Extending the use of unrelated umbilical cord blood cells for patients with hematological diseases. Best Pract Res Clin Haematol 2010;23:223–229.
91. Robinson SN, Thomas MW, Simmons PJ et al. Fucosylation with fucosyltransferase VI or fucosyltransferase VII improves cord blood engraftment. Cytotherapy 2014;16:84–89.
92. Durand B, Eddleman K, Migliaccio AR et al. Long-term generation of colony-forming cells (CFC) from CD34+ human umbilical cord blood cells. Leuk Lymphoma 1993;11:263–273.
93. Kurata H, Takakuwa K, Tanaka K. Ex vivo expansion of hematopoietic progenitor cells in human cord blood: An effect enhanced by cord blood serum. Hematol Pathol 1995;9:73–78.
94. Bertolini F, Soligo D, Lazzari L et al. The effect of interleukin-12 in ex-vivo expansion of human haemopoietic progenitors. Br J Hae-matol 1995;90:935–938.
95. Siena S, Di Nicola M, Bregni M et al. Massive ex vivo generation of functional dendritic cells from mobilized CD34+ blood progenitors for anti-cancer therapy. Exp Hematol 1995;23:1463–1471.
96. DiGiusto DL, Lee R, Moon J et al. Hemato-poietic potential of cryopreserved and ex vivo manipulated umbilical cord blood progenitor cells evaluated in vitro and in vivo. Blood 1996;87:1261–1271.
97. Scaradavou A, Isola L, Rubinstein P et al. A murine model for human cord blood transplantation: Near-term fetal and neonatal peripheral blood cells can achieve long-term bone marrow engraftment in sublethally irradiated adult recipients. Blood 1997;89:1089–1099.
98. Ohmizono Y, Sakabe H, Kimura T et al. Thrombopoietin augments ex vivo expansion of human cord blood-derived hematopoietic progenitors in combination with stem cell factor and flt3 ligand. Leukemia 1997;11:524–530.
99. De Bruyn C, Delforge A, Bron D et al. Ex vivoexpansionofCD34+CD38-cordbloodcells. J Hematother 1997;6:93–102.
100. Piacibello W, Sanavio F, Garetto L et al. Extensive amplification and self-renewal of human primitive hematopoietic stem cells from cord blood. Blood 1997;89:2644–2653.
101. Kögler G, Callejas J, Sorg RV et al. The effect of different thawing methods, growth factor combinations and media on the ex vivo expansion of umbilical cord blood primitive and committed progenitors. Bone Marrow Transplant 1998;21:233–241.
102. Kögler G, Callejas J, Sorg RV et al. An eight-fold ex vivo expansion of long-term culture-initiating cells from umbilical cord blood in stirred suspension cultures. Bone Marrow Transplant 1998;21(suppl 3):S48–S53.
103. Köhler T, Plettig R, Wetzstein W et al. Defining optimum conditions for theexvivo expansion of human umbilical cord blood cells. Influences of progenitor enrichment, interference with feeder layers, early-acting cytokines and agitation of culture vessels. Stem Cells 1999;17:19–24.
104. Nakamura Y, Ando K, Chargui J et al. Ex vivo generation of CD34(+) cells from CD34(2) hematopoietic cells. Blood 1999;94:4053–4059.
105. McNiece I, Kubegov D, Kerzic P et al. Increased expansion and differentiation of cord blood products using a two-step expansion culture. Exp Hematol 2000;28:1181–1186.
106. Lewis ID, Almeida-Porada G, Du J et al. Umbilical cord blood cells capable of engrafting in primary, secondary, and tertiary xenogeneic hosts are preserved after ex vivo culture in a noncontact system. Blood 2001;97:3441–3449.
107. Pecora AL, Stiff P, Jennis A et al. Prompt and durable engraftment in two older adult patients with high risk chronic myelogenous leukemia (CML) usingexvivo expanded and un-manipulated unrelated umbilical cord blood. Bone Marrow Transplant 2000;25:797–799.
108. Broxmeyer HE, Srour EF, Hangoc G et al. High-efficiency recovery of functional hemato-poietic progenitor and stem cells from human cordbloodcryopreservedfor15years. ProcNatl Acad Sci USA 2003;100:645–650.
109. Jaroscak J, Goltry K, Smith A et al. Augmentation of umbilical cord blood (UCB) transplantation with ex vivo-expanded UCB cells: Results of a phase 1 trial using the Aastrom Replicell System. Blood 2003;101: 5061–5067.
110. Peled T, Mandel J, Goudsmid RN et al. Pre-clinical development of cord blood-derived progenitor cell graft expanded ex vivo with cytokines and the polyamine copper chela-tor tetraethyllenepentamine. Cytotherapy 2004; 6:344–355.
111. Serrano LM, Pfeiffer T, Olivares S et al. Differentiation of naive cord-blood T cells into CD19-specific cytolytic effectors for posttrans-plantation adoptive immunotherapy. Blood 2006;107:2643–2652.
112. Chaurasia P, Gajzer DC, Schaniel C et al. Epigenetic reprogramming induces the expansion of cord blood stem cells. J Clin Invest 2014;124:2378–2395.
113. Bart T, Boo M, Balabanova S et al. Impact of selection of cord blood units from the United States and swiss registries on the cost of banking operations. Transfus Med Hemother 2013;40:14–20.
114. Delaney C, Bollard CM, Shpall EJ. Cord blood graft engineering. Biol Blood Marrow Transplant 2013;19(suppl):S74–S78.